Covgoze For Intramuscular Injection (Jn.1-Adapted), Recombinant Protein Covid-19 Vaccine, Receives Partial Change Approval In Japan
16/09/2026 07:02
BRIEF-Shionogi & Co., Ltd.- Covgoze For Intramuscular Injection (Jn.1-Adapted), Recombinant Protein Covid-19 Vaccine, Receives Partial Change Approval In Japan Sept 16 (Reuters) - Shionogi & Co., Ltd. 4507.T:
SHIONOGI & CO., LTD.: COVGOZE FOR INTRAMUSCULAR INJECTION (JN.1-ADAPTED), RECOMBINANT PROTEIN COVID-19 VACCINE, RECEIVES PARTIAL CHANGE APPROVAL IN JAPAN
Source text: ID:nTSup8328e
Further company coverage: 4507.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Shionogi & Co.
See all newsShionogi Continues Rare Disease Expansion With Planned Acquisition Of Intrabio Inc
Covgoze For Intramuscular Injection (Jn.1-Adapted), Recombinant Protein Covid-19 Vaccine, Receives Partial Change Approval In Japan
Notice Regarding Approval Of An Additional Dosage And Administration Of Vtama Cream For Pediatric Atopic Dermatitis (Under Age12) In Japan
Announces U.S. Government Procurement Of Fetroja (Cefiderocol) Through Barda's Project Bioshield
Media: Shionogi CEO pursues drug deals, mulls expanded US production - Bloomberg News